In yesterday’s Wall Street session, Roivant Sciences Ltd. (NASDAQ:ROIV) shares traded at $9.23, up 0.11% from the previous session.
9 analysts cover Roivant Sciences Ltd. (NASDAQ:ROIV), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $19.00 and a low of $10.00, we find $14.00. Given the previous closing price of $9.22, this indicates a potential upside of 51.84 percent. ROIV stock price is now 11.22% away from the 50-day moving average and 40.60% away from the 200-day moving average. The market capitalization of the company currently stands at $6.83B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $14.00 as their price target over the next twelve months.
In other news, Venker Eric, President & COO sold 415 shares of the company’s stock on May 23. The stock was sold for $4,088 at an average price of $9.85. Upon completion of the transaction, the President & COO now directly owns 675,768 shares in the company, valued at $6.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 09, President & COO Venker Eric sold 238,724 shares of the business’s stock. A total of $2,203,423 was realized by selling the stock at an average price of $9.23. This leaves the insider owning 675,768 shares of the company worth $6.24 million. A total of 14.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ROIV stock. A new stake in Roivant Sciences Ltd. shares was purchased by WELLINGTON MANAGEMENT GROUP LLP during the first quarter worth $111,026,000. OCTAGON CAPITAL ADVISORS LP invested $36,034,000 in shares of ROIV during the first quarter. In the first quarter, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) acquired a new stake in Roivant Sciences Ltd. valued at approximately $16,153,000. FRANKLIN RESOURCES INC acquired a new stake in ROIV for approximately $14,999,000. CANTOR FITZGERALD, L. P. purchased a new stake in ROIV valued at around $10,075,000 in the second quarter. In total, there are 162 active investors with 51.20% ownership of the company’s stock.
On Thursday morning Roivant Sciences Ltd. (NASDAQ: ROIV) stock kicked off with the opening price of $9.26. During the past 12 months, Roivant Sciences Ltd. has had a low of $2.87 and a high of $10.00. As of last week, the company has a debt-to-equity ratio of 0.43, a current ratio of 6.70, and a quick ratio of 6.70. The fifty day moving average price for ROIV is $8.31 and a two-hundred day moving average price translates $6.59 for the stock.
The latest earnings results from Roivant Sciences Ltd. (NASDAQ: ROIV) was released for Dec, 2022. According to the Biotechnology Company, earnings per share came in at -$0.49, missing analysts’ expectations of -$0.39 by -0.1. This compares to -$0.45 EPS in the same period last year. The company reported revenue of $17.05 million for the quarter, compared to $24.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -29.95 percent. For the current quarter, analysts expect ROIV to generate $20.45M in revenue.
Roivant Sciences Ltd.(ROIV) Company Profile
Roivant Sciences Ltd. focuses on discovery, development, and commercialization of medicines. It develops transformative medicines by building technologies and developing talent in creative ways, leveraging its platform to launch Vants nimble and focuses biopharmaceutical and health technology companies. The company was founded in 2014 and is based in London, the United Kingdom.
